相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Progression Risk Stratification of Asymptomatic Waldenstrom Macroglobulinemia
Mark Bustoros et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Comparing apples to oranges: A commentary on the Mayo study of MYD88 significance in Waldenstrom's macroglobulinemia. Reply
Jithma P. Abeykoon et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
MYD88 mutated and wild-type Waldenstrom's Macroglobulinemia: characterization of chromosome 6q gene losses and their mutual exclusivity with mutations in CXCR4
Maria Luisa Guerrera et al.
HAEMATOLOGICA (2018)
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
R. Schmitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
MYD88 mutated and wild-type Waldenstrom's Macroglobulinemia: characterization of chromosome 6q gene losses and their mutual exclusivity with mutations in CXCR4
Maria Luisa Guerrera et al.
HAEMATOLOGICA (2018)
Predictors of symptomatic hyperviscosity in Waldenstrom macroglobulinemia
Jithma P. Abeykoon et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Loss of TNFAIP3 enhances MYD88 L265P- driven signaling in non-Hodgkin lymphoma
Kerstin Wenzl et al.
BLOOD CANCER JOURNAL (2018)
Insights into the genomic landscape of MYD88 wild-type Waldenstrom macroglobulinemia
Zachary R. Hunter et al.
BLOOD ADVANCES (2018)
MYD88 wild-type Waldenstrom Macroglobulinaemia: differential diagnosis, risk of histological transformation, andoverall survival
Steven P. Treon et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
MYD88 mutation status does not impact overall survival in Waldenstrom macroglobulinemia
Jithma P. Abeykoon et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Diagnosis and Management of Waldenstrom Macroglobulinemia Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016
Prashant Kapoor et al.
JAMA ONCOLOGY (2017)
Transformed Waldenstrom macroglobulinaemia: clinical presentation and outcome. A multi-institutional retrospective study of 77 cases from the French Innovative Leukemia Organization (FILO)
Eric Durot et al.
BRITISH JOURNAL OF HAEMATOLOGY (2017)
Histological transformation to diffuse large B-cell lymphoma in patients with Waldenstrom macroglobulinemia
Jorge J. Castillo et al.
AMERICAN JOURNAL OF HEMATOLOGY (2016)
Hodgkin transformation of chronic lymphocytic leukemia: Incidence, outcomes, and comparison to de novo Hodgkin lymphoma
Sameer A. Parikh et al.
AMERICAN JOURNAL OF HEMATOLOGY (2015)
The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis
Zachary R. Hunter et al.
BLOOD (2014)
Activation of TAK1 by MYD88 L265P drives malignant B-cell Growth in non-Hodgkin lymphoma
S. M. Ansell et al.
BLOOD CANCER JOURNAL (2014)
MYD88 L265P in Waldenstrom macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction
Lian Xu et al.
BLOOD (2013)
Rates and Outcomes of Follicular Lymphoma Transformation in the Immunochemotherapy Era: A Report From the University of Iowa/Mayo Clinic Specialized Program of Research Excellence Molecular Epidemiology Resource
Brian K. Link et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenstrom's macroglobulinemia
C. Jimenez et al.
LEUKEMIA (2013)
Heterogeneity of Histological Transformation Events in Waldenstrom's Macroglobulinemia (WM) and Related Disorders
R. G. Owen et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2011)
Oncogenically active MYD88 mutations in human lymphoma
Vu N. Ngo et al.
NATURE (2011)
Biological and clinical risk factors of chronic lymphocytic leukaemia transformation to Richter syndrome
Davide Rossi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2008)
Population-Based Analysis of Incidence and Outcome of Transformed Non-Hodgkin's Lymphoma
Abdulwahab J. Al-Tourah et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma
Silvia Montoto et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP
Laurie H. Sehn et al.
BLOOD (2007)
Revised response criteria for malignant lymphoma
Bruce D. Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray
CP Hans et al.
BLOOD (2004)
Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia:: Consensus panel recommendations from the second international workshop on Waldenstrom's macroglobulinemia
RA Kyle et al.
SEMINARS IN ONCOLOGY (2003)
Waldenstrom macroglobulinaemia:: presenting features and outcome in a series with 217 cases
R García-Sanz et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
分享论文
